BioAge Labs (BIOA) CFO converts 3,542 options into common stock

Rhea-AI Filing Summary

BioAge Labs, Inc. CFO Dov A. Goldstein reported an option exercise and related stock acquisition. On January 16, 2026, he exercised a stock option for 3,542 shares of common stock at an exercise price of $4.38 per share, coded as an "M" transaction.

The derivative table shows this option carried a conversion price of $4.38 and an expiration date of February 17, 2035. Following the transaction, Goldstein held 25,950 shares of BioAge common stock directly and 166,458 stock options directly. The option vests in equal monthly installments of 1/48th of the total award, starting on February 1, 2025, contingent on continued service.

Insider Trade Summary

3,542 shares exercised/converted

Mixed 2 txns

Insider GOLDSTEIN DOV A MD

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,542	$0.00	--
Exercise	Common Stock	3,542	$4.38	$16K

Holdings After Transaction: Stock Option (Right to Buy) — 166,458 shares (Direct); Common Stock — 25,950 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSTEIN DOV A MD

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		M		3,542	A	$4.38	25,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.38	01/16/2026		M			3,542	(1)	02/17/2035	Common Stock	3,542	$0	166,458	D

Explanation of Responses:

1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in BioAge Labs (BIOA) Form 4 and what is their role?

The insider is Dov A. Goldstein, who serves as Chief Financial Officer of BioAge Labs, Inc. and filed the Form 4 as a single reporting person.

What transaction did BioAge Labs (BIOA) CFO Dov Goldstein report on January 16, 2026?

On January 16, 2026, CFO Dov A. Goldstein exercised a stock option, converting 3,542 derivative securities into 3,542 shares of common stock in a transaction coded "M."

How many BioAge Labs (BIOA) shares did the CFO acquire and at what price?

He acquired 3,542 shares of BioAge Labs common stock at a price of $4.38 per share through the option exercise reported on the Form 4.

What are Dov Goldstein’s holdings in BioAge Labs (BIOA) after this Form 4 transaction?

After the reported transaction, Dov A. Goldstein directly owned 25,950 shares of common stock and 166,458 stock options in BioAge Labs, Inc.

What are the key terms of the BioAge Labs (BIOA) stock option exercised by the CFO?

The stock option has an exercise price of $4.38 per share, an expiration date of February 17, 2035, and vests as to 1/48th of the total award monthly, starting on February 1, 2025, subject to continued service.

Is the BioAge Labs (BIOA) CFO’s ownership reported as direct or indirect on the Form 4?

Both the 25,950 common shares and the 166,458 stock options held after the transaction are reported as direct (D) ownership by Dov A. Goldstein.